It is becoming increasingly clear that signaling via G proteincoupled receptors is a diverse phenomenon involving receptor interaction with a variety of signaling partners. Despite this diversity, receptor ligands are commonly classified only according to their ability to modify G protein-dependent signaling. Here we show that ␤2AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1͞2 thus behaving as dual efficacy ligands. ERK1͞2 activation by dual efficacy ligands was not affected by ADP-ribosylation of G␣i and could be observed in S49-cyc ؊ cells lacking G␣s indicating that, unlike the conventional agonist isoproterenol, these drugs induce ERK1͞2 activation in a Gs͞i-independent manner. In contrast, this activation was inhibited by a dominant negative mutant of ␤-arrestin and was abolished in mouse embryonic fibroblasts lacking ␤-arrestin 1 and 2. The role of ␤-arrestin was further confirmed by showing that transfection of ␤-arrestin 2 in these knockout cells restored ICI118551 promoted ERK1͞2 activation. ICI118551 and propranolol also promoted ␤-arrestin recruitment to the receptor. Taken together, these observations suggest that ␤-arrestin recruitment is not an exclusive property of agonists, and that ligands classically classified as inverse agonists rely exclusively on ␤-arrestin for their positive signaling activity. This phenomenon is not unique to ␤2-adrenergic ligands because SR121463B, an inverse agonist on the V2 vasopressin receptor-stimulated adenylyl cyclase, recruited ␤-arrestin and stimulated ERK1͞2. These results point to a multistate model of receptor activation in which ligand-specific conformations are capable of differentially activating distinct signaling partners.
T
he signaling unit for G protein-coupled receptors (GPCRs) has been classically defined as consisting of the receptor, an heterotrimeric G protein and enzymatic or channel effectors controlling second messenger production or ion fluxes that regulate cell function. More recently it has become clear that GPCRs may also stimulate a variety of signaling systems that regulate cell proliferation and differentiation such as mitogenactivated protein kinases (MAPKs), extracellular signalregulated kinase (ERK) 1͞2, c-Jun-NH 2 -terminal kinase (JNK) 3, and p38 (1) . In many cases, mitogenic signals generated by GPCRs involve classical second messenger-dependent pathways (2) , but in others, they require the formation of metastable complexes that comprise the receptor, accessory proteins such as ␤-arrestins or ASK1 and effectors molecules such as Src, Ras, ERK1͞2, JNK, and MAPK kinase 4 (MKK4) (3) (4) (5) (6) .
Despite this growing diversity in GPCR signaling mechanisms, our definition of drug efficacy is still linked to a scheme considering only the regulation of the classical G protein signaling. Within this framework, agonists are defined as drugs that stabilize an active receptor conformation that induces G protein activation, whereas inverse agonists favor an inactive receptor state that reduces spontaneous G protein signaling (7) . The question that now arises is whether this same paradigm may be transferred to drug effects generated through the formation of metastable complexes involving scaffolding proteins such as ␤-arrestin. Because all studies describing ␤-arrestin-mediated MAPK signaling have concentrated on agonist drugs, little is known of how ligands that are commonly classified as inverse agonists may regulate the scaffold assembly that is crucial for such signaling.
In the present study, this question was addressed by assessing whether ␤ 2 -adrenergic receptor (␤ 2 AR) ligands with proven inverse efficacy on adenylyl cyclase (AC) activity could also regulate MAPK activation via receptor-mediated scaffold formation. We found that, despite being inverse agonists in the AC pathway, ICI118551, and propranolol induced the recruitment of ␤-arrestin leading to the activation of the ERK cascade. Such observations indicate that the same drug acting on a unique receptor can have opposite efficacies depending on the signaling pathway considered.
Materials and Methods
Expression Vectors. Wild-type ␤2AR and V2 vasopressin receptor (V2R).
Wild-type human ␤ 2 AR, V2R, and hemagglutinin (HA)-tagged (YPYDVPDYA) ␤ 2 AR sequences were subcloned into a modified pcDNA3 vector (Invitrogen) in which the cytomegalovirus promoter was replaced by a Rous sarcoma virus promoter as described (8) . V2R-GFP and ␤2AR-GFP. The coding sequence of the green fluorescent protein variant GFP 10 (9) was inserted in-frame 3Ј of the wild-type V2R sequence into pcDNA3-V2R so that a 14-aa linker (GSGTAGPGSPPVAT), separates the carboxyl tail of the receptor and the initiator methionine of GFP10. For the ␤ 2 AR-GFP, a GFP10 AgeI͞BsrgI fragment was subcloned into the AgeI͞BsrgI site of pGFP-N1-His␤ 2 AR-YFP (10) to yield pGFP-N1-His␤ 2 AR-GFP10. ␤-Arrestin-Rluc. The rat ␤-arrestin 2 coding sequence was inserted in-frame 5Јof the Renilla luciferase sequence in the pRluc vector (Perkin-Elmer) so that a 7-aa linker (GAGALAT) separates the carboxyl terminal of ␤-arrestin and the initiator methionine of Rluc. ␤-Arrestin-YFP. The rat ␤-arrestin 2 coding sequence was amplified out of its original vector with two NheI site-containing primers to generate a stop codon-free fragment that was then subcloned in-frame 3Ј into the NheI site of a yellow variant GFP-topaz vector (pGFP-N1-Topaz, Packard; ref. 10). All constructs were confirmed by sequencing.
Cell Culture and Transfections. Mouse embryonic fibroblasts (MEFs), HEK293 and Cos1 cells were grown in DMEM supplemented with 10% FBS, 2 mM glutamine, 0.1 units͞ml penicillin, 0.1 mg͞ml streptomycin, and 0.25 g͞ml fungizone. S49 mouse lymphoma T cells were grown in DMEM as above but supplemented with 10% heat-inactivated horse serum. Freshly dispersed cardiomyocytes were prepared as described (11) . Calcium phosphate precipitation and G418 selection pressure (450 g͞ml) were used to produce stable HEK293 cell lines expressing ␤ 2 AR or V2R. MEFs were transiently transfected by using FuGENE 6 (Roche Molecular Biochemicals) according to supplier's specifications. All other transient transfections were carried out by calcium phosphate precipitation. Cells were cultivated under sterile conditions at 37°C in a 5% CO 2 atmosphere.
MAPK Activity, cAMP Accumulation, and Gene Reporter Assays. For ERK1͞2 phosphorylation assays, cells were grown in six-well plates, serum-starved overnight and then incubated in PBS, at 37°C in the presence of different ligands. Cells were lysed in sample buffer and separated on SDS͞10% PAGE, according to the method of Laemmli (12) . Proteins were transferred onto nitrocellulose and Western blot analysis carried out by using a 1:5,000 dilution of mouse monoclonal antiphospho-ERK1͞2 antibody (Santa Cruz Biotechnology). Total ERK protein was determined by using a 1:20,000 dilution of anti-ERK antibody (Santa Cruz Biotechnology). Blots were then probed with antimouse or anti-rabbit horseradish peroxydase-conjugated secondary antibodies, visualized by using enhanced chemiluminescence reagent (Amersham Pharmacia) and quantified by densitometric analysis. ERK1͞2 phosphorylation was normalized according to the loading of proteins by expressing the data as a ratio of phospho-ERK1͞2 over total ERK1͞2. Results were expressed as percentage of the value obtained in nonstimulated cells.
For cAMP accumulation assays, cells were incubated for 16 h with [ 3 H]adenine (2 Ci͞ml; 1 Ci ϭ 37 GBq) and washed twice before stimulation with the indicated drugs at 37°C. After a 15-min incubation, the reaction was stopped by adding 1 ml of ice-cold 5% trichloroacetic acid and 1 mM of unlabeled cAMP. For gene reporter assays, HEK293 cells stably expressing the ␤ 2 AR were transiently transfected with pFA-Elk1 and pFR-Luc reporter plasmids of the PathDetect Reporting System (Stratagene), by using calcium phosphate precipitation procedure. After a 6-h incubation with the indicated ligands, luciferase activity was measured in cell lysates by using a firefly luciferase assay kit (Promega) and a LumiCount luminometer (Packard), as described (13) .
Bioluminescence Resonance Energy Transfer (BRET) Assay. BRET is a proximity assay based on the nonradiative transfer of energy between a donor (luciferase) and an acceptor (GFP). It was used to assess ␤-arrestin recruitment to ␤ 2 AR or V2R as described (10) . Briefly, fusion proteins consisting of the GFP-10 variant (9), covalently attached to the carboxyl tail of the receptor of interest (␤ 2 AR-GFP; V2R-GFP), were coexpressed with ␤-arrestin 2 fused at its carboxyl terminus to Rluc (␤-arrestin-Rluc). After incubation of the transfected cells with different ligands, Deep Blue coelanterazine (Packard) was added at a final concentration of 5 M and readings were collected by using a modified top-count apparatus (BRETCount, Packard) that allows the sequential integration of the signals detected in the 370-to 450-and 500-to 530-nm windows. The BRET signal was determined by calculating the ratio of the light emitted by the Receptor-GFP (500-530 nm) over the light emitted by the ␤-arrestin-2-Rluc (370-450 nm). The values were corrected by subtracting the background signal detected when the ␤-arrestin-2-Rluc construct was expressed alone.
Immunofluorescence and Confocal Microscopy. Immunofluorescence microscopy was carried out in Cos1 cells transiently transfected either with a HA-tagged ␤ 2 V2R chimera (consisting of the first 341 aa of the ␤ 2 AR and the last 29 aa of the V2) and ␤-arrestin-2-GFP or HA-tagged ␤ 2 AR and ERK2 GFP by using FuGENE 6. Immunolabeling of the HA-tagged ␤ 2 V2R and ␤ 2 AR was carried out in nonpermeabilized cells by using the anti-HA (12CA5; 1:100) antibody. Immunoreactivity was revealed by using a Texas red-conjugated secondary antibody. ␤-arrestin-GFP and ERK2-GFP were visualized by direct fluorescence detection. Quantitative assessment of nuclear translocation of ERK2-GFP was carried out by counting the number of cells in which GFP fluorescence colocalized with the nuclear marker To-Pro-3 iodine (Molecular Probes). All confocal microscopy images were acquired on a Leica HM IRBE laserscanning microscope with a ϫ100 objective.
Results and Discussion
HEK293 fibroblasts stably expressing the ␤ 2 AR were used to compare the effects of different ␤ 2 AR ligands on the classical G␣s-mediated activation of the AC pathway and the MAPK cascade. As previously reported (14, 15) , isoproterenol behaved as an agonist in the two systems, leading to increased cAMP production and ERK1͞2 phosphorylation ( Fig. 1 A and B) . Also in agreement with previous reports (14), propranolol and ICI118551 produced inverse agonist effects for the AC pathway, inhibiting cAMP production by 35% and 50%, respectively (Fig.  1 A) . However, these two compounds were found to be agonists at the MAPK cascade, with propranolol inducing a 67% increase and ICI118551 inducing a 52% increase in ERK1͞2 phosphorylation (Fig. 1B) . Timolol, was devoid of intrinsic activity in the two pathways ( Fig. 1 A and C) but competitively blocked both inverse agonist (ref. 14 and data not shown) and agonist (Fig. 1C) effects of ICI118551.
Opposing effects of ICI118551 and propranolol on AC and MAPK activity cannot be attributed to an artifact related to receptor overexpression in HEK293 cells because their dual actions were also observed in Cos1 (Fig. 1B Inset) , S49 cells (see below), and cardiomyocytes (Fig. 1D ) all of them endogenously expressing low levels of ␤ 2 AR. The activation kinetics of MAPK by isoproterenol, ICI118551, and propranolol were similar; activation was fast and transient, and reached a peak between 1 and 2 min after drug addition (Fig. 1D) . However, the effects of ICI118551 and propranolol appear to be slightly slower because their maximal activity was observed at 2 min rather than at 1 min, as for isoproterenol.
Consistent with the known longer-term nuclear translocation of activated ERK, both isoproterenol and ICI118551 promoted targeting of ERK2-GFP to the nucleus after a 20-min treatment with the drugs (Fig. 2A) . As is the case for isoproterenol, ERK nuclear translocation promoted by dual efficacy drugs ICI118551 and propranolol also has functional consequences as illustrated by increased Elk-dependent transcriptional activity (Fig. 2B) . Given the role played by ERK in ␤-adrenergic-mediated cardiac fibroblast hypertrophy and the general use of ␤ 2 AR antagonists and inverse agonists in the treatment of hypertension and heart failure (16), the agonistic properties of these compounds on the ERK pathway could have clinically relevant implications.
Because both G␣s (2, 15, 17) and G␣i (15, 18) have been shown to contribute to MAPK activation by the conventional agonist isoproterenol, we sought to determine whether this was also the case for drugs with dual efficacy like propranolol or ICI118551. The possible role of G␣s was assessed by comparing the effects of ICI118551 and isoproterenol in S49 wild-type and S49 cyc Ϫ cells that lack G␣s (19) . As shown in Fig. 3A , both isoproterenol and ICI118551 promoted ERK phosphorylation in wild-type S49 cells, but only ICI118551 activated the kinase in the cyc Ϫ cells, indicating that G␣s is not needed for MAPK activation by dual efficacy drugs. To test the potential implication of G␣i͞o, HEK293 cells were pretreated with pertussis toxin (PTX). The treatment abolished MAPK activation by a typical G␣i͞o coupled ␦-opioid receptor but was without effect on ERK phosphorylation induced by ICI118551 (Fig. 3B) , ruling out a role for G␣i͞o in this response. In keeping with previous observations (15, 18) where MAPK activation by isoproterenol has been shown to require the sequential activation of G␣s and G␣i͞o, the agonist response was not only absent in the S49 cyc Ϫ cells, but was also significantly inhibited by PTX treatment.
Taken together, these results indicate that unlike isoproterenol, ICI118551 activates the MAPK signaling pathway independently of G␣i and G␣s. The lack of G protein involvement is further supported by the observation that overexpression of the carboxyl tail of GRK2, which acts as a scavenger of G␤␥ (20), did not modify ICI118551-stimulated ERK1͞2 phosphorylation (data not shown). G protein-independent activation of MAPK has been recently documented for mutants of the angiotensin II type 1 receptors that fail to couple to their cognate G proteins (21) . This finding may indicate that G protein-independent MAPK signaling is a general feature of heptahelical receptors, unveiled when G protein coupling is prevented either as a result of mutations or after the stabilization of the receptor by ligands such as ICI118551 or propranolol that inhibit receptor-G protein interaction.
The nonreceptor tyrosine kinase Src is an intermediate in diverse pathways leading to MAPK activation by GPCRs (1, 3, 22) whether they involve G protein signaling (15) or not (21) . As shown in Fig. 4A , G protein-independent activation of ERK by ICI118551 was also found to involve Src activation because it was blocked by the selective Src inhibitor PP2. Several mechanisms of Src activation by GPCRs have been proposed (1) . For the ␤ 2 AR, isoproterenol stimulation has been shown to promote the recruitment of Src through an indirect interaction that involves the proline-rich motif of ␤-arrestin and the Src homology 3 domain of Src (3). In addition to its adaptor role, bridging the receptor and Src, ␤-arrestin has been shown to function as a scaffold protein organizing the assembly of Raf, MAP͞ERK kinase, ERK͞ASK1, MKK4, and JNK3 modules for an increasing number of GPCRs (4) (5) (6) 23) . We therefore examined the role of ␤-arrestin in promoting ERK1͞2 activity by ICI118551. To do so, we first used a dominant negative mutant corresponding to the carboxyl-terminal fragment (␤arr319-418) of ␤-arrestin, previously shown to decrease ERK1͞2 activation by isoproterenol (24) . Similar to the isoproterenol response, ICI118551 activation of ERK1͞2 was inhibited by ␤arr319-418 (Fig. 4B) , suggesting that ␤-arrestin also mediates the MAPK stimulation by dual efficacy drugs. The role of ␤-arrestin in ERK1͞2-activation by ICI118551 was further documented by using MEFs derived from knockout (KO) animals lacking ␤-arrestin 1 and 2 (␤arr-DKO) (25) . In contrast with the significant ERK phosphorylation induced by isoproterenol and ICI118551 in wildtype MEFs, neither drug activated the MAPK pathway in the ␤arr-DKO cells (Fig. 4C) . However, the ERK1͞2 response to ICI118551 was restored on transient transfection of ␤-arrestin 2 into double KO (DKO) cells (Fig. 4C) confirming its role as an adaptor͞scaffolding protein in this pathway.
␤-arrestins have been extensively characterized as regulators of agonist-induced GPCR signaling (26) , and their role in agonist-promoted desensitization and receptor internalization are well defined. Classically, ␤-arrestins are recruited to the membrane by the agonist-occupied state of the receptor. Once this association takes place, the receptor is uncoupled from the G protein (27) and targeted to the endocytic compartment (28) via direct interactions with proteins of clathrin-coated pits (29) (30) (31) . The observation that ICI118551 relies on ␤-arrestin to induce MAPK activation suggests that, in addition to classical agonists, some drugs normally classified as ''inverse agonists'' can also promote the recruitment of ␤-arrestin.
This hypothesis was tested by assessing ligand-promoted ␤-arrestin recruitment using immunofluorescence microscopy. In Cos1 cells coexpressing HA-tagged ␤ 2 AR and ␤-arrestin-GFP, a modest translocation of ␤-arrestin to the membrane could be observed on stimulation with isoproterenol but not ICI118551 or propranolol (data not shown). We reasoned that this negative result could be caused by a combination of factors. First, the ␤ 2 AR belongs to a class of GPCRs known to have relatively low affinity for ␤-arrestin, leading to only transient complexes between the two proteins (31) . Second, when compared with isoproterenol, ICI118551 and propranolol display partial agonistic activities toward MAPK signaling and their reduced efficacy could have caused incomplete ␤-arrestin recruitment that went undetected. To overcome these limitations, we took advantage of the fact that V2R interacts more tightly than ␤ 2 AR with ␤-arrestin (31). Because this property has been mapped to the last 10 aa of the V2R tail, we used a receptor chimera consisting of the first 341 aa of the ␤ 2 AR fused to the last 29 aa of the V2R. This chimera has previously been shown to have high affinity for ␤-arrestin (31). As shown in Fig. 5A , isoproterenol and ICI118551 promoted a robust translocation of ␤-arrestin-GFP to the membrane of Cos1 cells expressing the chimeric ␤ 2 V2R. In contrast, vasopressin, which does not bind the chimera, was without effect on ␤-arrestin cell distribution (data not shown).
The results presented above are consistent with the notion that binding of compounds such as ICI118551 and propranolol can stabilize a receptor conformation that allows ␤-arrestin binding to a chimeric ␤ 2 V2R receptor, but did not prove that this can occur for the wild-type ␤ 2 AR. To directly assess the physical interaction between the ligand-bound ␤ 2 AR itself and ␤-arrestin, we turned to a more sensitive assay based on BRET. For this, ␤ 2 AR-GFP and ␤-arrestin-Rluc were transiently coexpressed in HEK293 cells. As shown in Fig. 5B , isoproterenol, propranolol, and ICI118551 all induced ␤-arrestin recruitment, as indicated by an increase in the BRET signal. Consistent with the partial agonist effect of ICI118551 and propranolol on the MAPK activity, BRET increases promoted by these compounds were significantly smaller than the one induced by isoproterenol. This low efficacy of propranolol in promoting ␤-arrestin recruitment is consistent with previous immunofluorescence results showing that propranolol can inhibit isoproterenol-induced ␤-arrestin mobilization (29) . Such an inhibition is also seen in the BRET experiments where propranolol reduced the signal induced by isoproterenol to the level attained on stimulation with propranolol alone (Fig. 5B) .
Taken together, our observations suggest that, although they are inverse agonists on the G␣s-stimulated AC cascade, compounds such as ICI118551 and propranolol have partial agonist efficacy on the ␤-arrestin-dependent MAPK pathway. These findings are not consistent with a classical view proposing a unique ''activated'' receptor conformation involved in G protein coupling and ␤-arrestin recruitment. They are more in keeping with the emerging concept that distinct active conformations may be stabilized by different ligands (32) and that some of these conformations may favor activation of one effector over another (33) or induce differential recruitment of ␤-arrestin (34, 35) . For the systems considered herein, classical agonists like isoproterenol would stabilize a receptor state capable of activating G␣s and of promoting the recruitment of ␤-arrestin, whereas the conformation stabilized by ICI118551 or propranolol would interdict productive G protein coupling but favor ␤-arrestin engagement. Previous reports showing that some GPCR antagonists can promote receptor endocytosis (36, 37) , a phenomenon normally triggered by agonists, could also find their explanation in the concept of discrete receptor conformations that have only some of the properties of the fully active state. The idea that ␤-arrestin may interact with several distinct receptor conformations is also consistent with the observations that not only agonists (38) but also certain GPCR antagonists (39) display high affinity for the ␤-arrestin-bound form of the receptor.
In addition to demonstrating that ligands may have dual efficacies depending on the effector system considered, our study clearly shows that a single receptor can activate the MAPK through distinct mechanisms. Indeed, although both Gs and ␤-arrestin were found to be involved in the isoproterenolmediated activation, only ␤-arrestin contributes to the activation by ICI118551 and propranolol. Whether this difference in the MAPK activation mechanism between the two classes of ligands could underlie the modest difference in the activation kinetics observed in Fig. 1D remains to be determined.
To assess whether dual efficacy was unique to ␤ 2 AR ligands or whether it could be a general concept applicable to other seven transmembrane domain receptors, AC and MAPK regulation by V2R drugs was also examined. As shown in Fig. 6 A and B, SR121463B, a non-peptide V2R selective ligand, induced an inverse agonist response on the AC pathway but clearly stimulated MAPK activity in HEK293 cells stably expressing the human V2R, an observation that extends the concept of dual efficacy ligands to another GPCR. Similarly to what was observed for ICI118551 and propranolol at the ␤ 2 AR, SR121463B promoted the recruitment of ␤-arrestin to the V2R. Indeed, a time-dependent recruitment could be detected by BRET in HEK293 cells transiently coexpressing V2R-GFP and ␤-arrestinRluc (Fig. 6C) . In agreement with the partial agonist activity of SR121463B on the MAPK activity, its ␤-arrestin recruitment was also partial, with a BRET signal that reached 38% of the vasopressin-induced response. As expected, ICI118551 was without effect on the recruitment of ␤-arrestin to the V2R, confirming the selectivity of the response.
Overall, the results of the present study point to a general multistate model of receptor activation in which ligand-specific conformations are capable of differential activation of distinct signaling partners. This is reminiscent of the concept of ''trafficking of receptor stimulus'' (33, 40) previously proposed to explain that ligands can activate diverse effectors with distinct rank order of potencies and͞or efficacies. However, results presented herein add a new level of complexity, showing that a ligand can have opposing efficacies on two effector systems engaged by the same receptor, indicating that the ''direction'' of response can be influenced by the effector considered. The study also confirms ␤-arrestin in its role as a genuine signaling partner that can be involved in the G protein-independent signaling of seven transmembrane domain receptors.
